<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063968</url>
  </required_header>
  <id_info>
    <org_study_id>6019-CPK-1001</org_study_id>
    <nct_id>NCT05063968</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of XZP-6019 Tablets in Healthy Subjects</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics (PK) of XZP-6019 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanzhu Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanzhu Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food&#xD;
      Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A and Part C studies were designed as single-center, randomized, double-blind,&#xD;
      placebo-controlled, dose-escalation trials to assess the safety, tolerability,&#xD;
      pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single and multiple oral doses of&#xD;
      XZP-6019 tablets in healthy adult subjects. Part B is a single-center, randomized, open&#xD;
      label, 2×2 crossover design to assess the food effects on PK of a single oral dose of&#xD;
      XZP-6019 tablets in healthy adult subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Prior to dosing, 0.25,0.5,1,2,3,4,6,8,12,24,36,48,72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of adverse events for XZP-6019 versus placebo</measure>
    <time_frame>Part A: From signing Informed consent form to Day 16; Part B: From signing Informed consent form to Day 16; Part C: From signing Informed consent form to Day 42.</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Part A - Single Ascending Dose (SAD) phase: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Single Ascending Dose (SAD) phase:Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Food Effect (FE) phase: Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Food Effect (FE) phase: Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - multiple ascending dose (MAD) phase: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - multiple ascending dose (MAD) phase:Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-6019 tablet</intervention_name>
    <description>Tablet is administered orally once on Day 1 and Day 9, respectively</description>
    <arm_group_label>Part A - Single Ascending Dose (SAD) phase: Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet is administered orally once on Day 1 and Day 9, respectively</description>
    <arm_group_label>Part A - Single Ascending Dose (SAD) phase:Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-6019 tablet</intervention_name>
    <description>Tablet is administered fasted orally once on Day 1</description>
    <arm_group_label>Part B - Food Effect (FE) phase: Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-6019 tablet</intervention_name>
    <description>Tablet is administered after a high-fat meal orally once on Day 9</description>
    <arm_group_label>Part B - Food Effect (FE) phase: Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-6019 tablet</intervention_name>
    <description>Tablet is administered orally once daily for 14 Days continuously</description>
    <arm_group_label>Part C - multiple ascending dose (MAD) phase: Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet is administered orally once daily for 14 Days continuously</description>
    <arm_group_label>Part C - multiple ascending dose (MAD) phase:Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting all of the following criteria will be enrolled in this study.&#xD;
&#xD;
               1. Healthy adult males or females aged 18 to 45 years (including 18 and 45 years&#xD;
                  old).&#xD;
&#xD;
               2. Body weight ≥ 50 kg for males and ≥ 45 kg for female; body mass index (BMI) in&#xD;
                  the range of 19.0-26.0 kg/m2 for the non-obese cohort and in the range of 28.1&#xD;
                  -35.0 kg/m2 for the obese cohort (including the boundary value,&#xD;
                  BMI=weight/height2).&#xD;
&#xD;
               3. No plans for childbearing or donating sperm/egg within the latest 6 months, and&#xD;
                  willing to use effective contraception within 6 months after the end of dosing&#xD;
&#xD;
               4. No clinically significant findings in vital signs, physical examination,&#xD;
                  laboratory tests, or ECG or Lung CT for Low-dose.&#xD;
&#xD;
               5. Subjects understand and comply with the study procedures, voluntarily&#xD;
                  participate, and sign an Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting any of the following criteria will not be enrolled in this study:&#xD;
&#xD;
               1. With history or presence of clinically significant abnormalities, e.g.:&#xD;
                  significant abnormality or disease of endocrine, gastrointestinal,&#xD;
                  cardiovascular, hematologic, hepatic, immunologic, renal, respiratory,&#xD;
                  genitourinary or major neurological (including stroke and chronic epilepsy) or&#xD;
                  patients with psychosomatic disorders&#xD;
&#xD;
               2. History of clinically significant ECG abnormalities or family history of long QT&#xD;
                  syndrome (grandparents, parents and siblings), or&#xD;
&#xD;
                  Any of the following was regarded as a criterion for exclusion:&#xD;
&#xD;
                    1. Confirmation of QTcF ≥ 450 ms by repeated measurements;&#xD;
&#xD;
                    2. Confirmation of QRS duration &gt; 120 ms by repeated measurements;&#xD;
&#xD;
                    3. Confirmation of PR interval &gt; 200 ms by repeated measurements;&#xD;
&#xD;
                    4. Findings that make QTc measurement difficult or QTc data difficult to&#xD;
                       interpret;&#xD;
&#xD;
                    5. History of other risk factors for Torsades de Pointes tachycardia (e.g.,&#xD;
                       heart failure, hypokalemia, family history of long QT syndrome);&#xD;
&#xD;
                    6. Presence of uncorrected hypokalemia or hypomagnesemia.&#xD;
&#xD;
               3. Subjects with a known or suspected history of allergy to the test drug or its&#xD;
                  excipient components, or a history of clinically significant severe allergy&#xD;
                  (e.g., food, drug, latex allergy), or a history of atopic allergic disease&#xD;
                  (asthma, urticaria, eczematous dermatitis)&#xD;
&#xD;
               4. History of dysphagia or any gastrointestinal disorder affecting drug absorption&#xD;
                  at screening, including history of frequent nausea or vomiting of any etiology,&#xD;
                  history of irregular gastrointestinal motility such as habitual diarrhea,&#xD;
                  constipation or pre-irritable bowel syndrome, or history of major&#xD;
                  gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, bowel&#xD;
                  resection, gastric bypass, gastric division, or gastric banding)&#xD;
&#xD;
               5. History of pancreatic injury or pancreatitis at screening, or significantly&#xD;
                  elevated blood amylase (&gt; 1.5 ULN)&#xD;
&#xD;
               6. History of urinary tract obstruction or presence of urinary voiding difficulties&#xD;
                  at screening.&#xD;
&#xD;
               7. History of cancer (malignancy) at the time of screening.&#xD;
&#xD;
               8. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis&#xD;
                  B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or syphilis antibody&#xD;
&#xD;
               9. History of significant drug abuse within 12 months prior to screening or positive&#xD;
                  urinary drug test at screening&#xD;
&#xD;
              10. Regular alcohol consumption within 3 months prior to screening, consuming more&#xD;
                  than 3 alcoholic drinks per day (one drink is approximately equal to: beer 354&#xD;
                  mL/12 oz, wine 118 mL/4 oz, or distilled spirits 29.5 mL/1 oz), or evidence of&#xD;
                  alcohol abuse and excessive consumption as evidenced by alcohol breath test at&#xD;
                  screening (subjects consuming 4 alcoholic drinks per day may be enrolled at the&#xD;
                  discretion of the investigator).&#xD;
&#xD;
              11. History of smoking within 3 months prior to screening, or a positive urinary&#xD;
                  nicotine test at screening, or who cannot give up smoking throughout the study&#xD;
                  period&#xD;
&#xD;
              12. Excessive daily intake of coffee, tea, cola, energy drinks, or other caffeinated&#xD;
                  beverages within 3 months prior to screening, with excess defined as more than 6&#xD;
                  servings (one serving is approximately equal to 120 mg of caffeine).&#xD;
&#xD;
              13. Major surgery, or donation or loss of blood over 400 mL within 3 months prior to&#xD;
                  administration.&#xD;
&#xD;
              14. Participation in other clinical trials and treatment with investigational product&#xD;
                  within 3 months prior to administration.&#xD;
&#xD;
              15. Take any prescription, over-the-counter, health product, herbal or proprietary&#xD;
                  Chinese medicine within 4 weeks prior to administration (or less than 5&#xD;
                  half-lives of the drug administration from the start of the trial).&#xD;
&#xD;
              16. Women who are pregnant or breastfeeding, or of childbearing potential who are not&#xD;
                  using effective non-hormonal contraception (intrauterine device (IUD), barrier&#xD;
                  method with spermicide, or surgical sterilization, etc.) or are unwilling to&#xD;
                  continue using these methods during the trial until 6 months after&#xD;
                  discontinuation; men of childbearing potential who are unwilling to use physical&#xD;
                  methods of contraception during the trial until 6 months after discontinuation.&#xD;
&#xD;
              17. At the time of screening, Systolic blood pressure ≥ 140 mmHg or &lt; 90 mmHg, and/or&#xD;
                  diastolic blood pressure ≥ 90 mmHg or &lt; 50 mmHg.&#xD;
&#xD;
              18. At the time of screening, Heart rate &lt; 50 or &gt; 100 beats/min.&#xD;
&#xD;
              19. Glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73m2 was estimated at screening&#xD;
                  according to the Chronic Kidney Disease Epidemic (CKD-EPI) formula (see Annex 1&#xD;
                  for calculation formula).&#xD;
&#xD;
              20. At screening, the liver function tests showed any measure of aminotransferase&#xD;
                  (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or total&#xD;
                  bilirubin is &gt; upper limit of normal (ULN) in non-obesity cohorts; liver function&#xD;
                  tests of obese group showed AST, ALT or ALP is &gt; 1.5 ULN, or total bilirubin is &gt;&#xD;
                  ULN in obesity cohort.&#xD;
&#xD;
              21. Fasting triglycerides &gt; 2.3mmol/L at the time of screening.&#xD;
&#xD;
              22. Fasting glucose &gt; 5.6 mmol/L in the non-obese cohort and &gt; 6.1 mmol/L or&#xD;
                  glycosylated hemoglobin (HbA1c) ≥ 6.5% in the obese group at screening.&#xD;
&#xD;
              23. Those who could not tolerate blood sample collection.&#xD;
&#xD;
              24. Subjects who are deemed by the investigator to be unsuitable for participation in&#xD;
                  the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Dong, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingjing Wu</last_name>
    <phone>+86-010-57654511</phone>
    <email>wujingjing@xuanzhupharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101125</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruihua Dong, Doctor</last_name>
      <phone>+86-13810461342</phone>
      <email>Ruihua_Dong_RW@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

